Laura Johnson, LPN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 1001 15th Ave Nw, Ardmore, OK 73401 Phone: 580-223-3737 Fax: 580-226-5679 |
Mrs. Jessica Laurynn Higgins, LPN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 2530 S Commerce St, Ardmore, OK 73401 Phone: 580-223-5070 |
Mary Jennifer Chaney, LPN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 2530 S Commerce St Bldg B, Ardmore, OK 73401 Phone: 580-223-5636 |
Ashley Wilson, Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 1219 K St Nw Ste 2, Ardmore, OK 73401 Phone: 580-319-7305 Fax: 580-319-5349 |
Shaquanna Wright, Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 2530 S Commerce St, Ardmore, OK 73401 Phone: 580-223-5636 Fax: 580-226-6727 |
Lisa Diane Bonham, LPN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 2530 S Commerce St, Ardmore, OK 73401 Phone: 580-223-5070 Fax: 580-226-3569 |
Jodi Coleman, Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 2530 S Commerce St, Ardmore, OK 73401 Phone: 580-223-5636 |
Dr. Charla Danielle Wells, LPN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 2530 S Commerce St, Ardmore, OK 73401 Phone: 580-223-5636 |
News Archive
Scientists at A*STAR'S Genome Institute of Singapore (GIS) and Institute of Molecular Biology (IMB), have made a breakthrough discovery in the understanding of lung regeneration. Their research showed for the first time that distal airway stem cells (DASCs), a specific type of stem cells in the lungs, are involved in forming new alveoli to replace and repair damaged lung tissue, providing a firm foundation for understanding lung regeneration.
Type 1 diabetes is not predominantly a 'disease of childhood' as previously believed, but is similarly prevalent in adults, new research published in the Lancet Diabetes & Endocrinology shows.
Enzon Pharmaceuticals, Inc. today announced its financial results for the second quarter of 2010. For the second quarter of 2010, Enzon reported a loss from continuing operations of $5.4 million or $0.09 per diluted share, as compared to a loss of $19.7 million or $0.43 per diluted share for the second quarter of 2009.
Combining the recently approved BRAF inhibitor, Zelboraf with an engineered T cell immunotherapy to treat metastatic melanoma significantly increased tumor responses and survival in an animal model, researchers at UCLA's Jonsson Comprehensive Cancer Center have shown.
Systemic lupus erythematosus (SLE) is an autoimmune disease that affects multiple organs. SLE severity is highly variable, and this variability is known to be partially dependent on ancestral background.
› Verified 9 days ago